|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Genome Atlas Research Network:
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moreira AL and Eng J: Personalized therapy
for lung cancer. Chest. 146:1649–1657. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong
W, Liao Y and Du J: High expression of miR-21 and miR-155 predicts
recurrence and unfavourable survival in non-small cell lung cancer.
Eur J Cancer. 49:604–615. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hayashita Y, Osada H, Tatematsu Y, Yamada
H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y and
Takahashi T: A polycistronic microRNA cluster, miR-17-92, is
overexpressed in human lung cancers and enhances cell
proliferation. Cancer Res. 65:9628–9632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Campayo M, Navarro A, Viñolas N, Diaz T,
Tejero R, Gimferrer JM, Molins L, Cabanas ML, Ramirez J, Monzo M
and Marrades R: Low miR-145 and high miR-367 are associated with
unfavourable prognosis in resected nonsmall cell lung cancer. Eur
Respir J. 41:1172–1178. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Osada H and Takahashi T: let-7 and
miR-17-92: Small-sized major players in lung cancer development.
Cancer Sci. 102:9–17. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nadal E, Chen G, Gallegos M, Lin L,
Ferrer-Torres D, Truini A, Wang Z, Lin J, Reddy RM, Llatjos R, et
al: Epigenetic inactivation of microRNA-34b/c predicts poor
disease-free survival in early stage lung adenocarcinoma. Clin
Cancer Res. 19:6842–6852. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luo W, Huang B, Li Z, Li H, Sun L, Zhang
Q, Qiu X and Wang E: MicroRNA-449a is downregulated in non-small
cell lung cancer and inhibits migration and invasion by targeting
c-Met. PLoS One. 8:e647592013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nasser MW, Datta J, Nuovo G, Kutay H,
Motiwala T, Majumder S, Wang B, Suster S, Jacob ST and Ghoshal K:
Downregulation of micro-RNA-1 (miR-1) in lung cancer. Suppression
of tumorigenic property of lung cancer cells and their
sensitization to doxorubicin-induced apoptosis by miR-1. J Biol
Chem. 283:33394–33405. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rao PK, Kumar RM, Farkhondeh M,
Baskerville S and Lodish HF: Myogenic factors that regulate
expression of muscle-specific microRNAs. Proc Natl Acad Sci USA.
103:8721–8726. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kondo N, Toyama T, Sugiura H, Fujii Y and
Yamashita H: miR-206 Expression is downregulated in estrogen
receptor alpha-positive human breast cancer. Cancer Res.
68:5004–5008. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Taulli R, Bersani F, Foglizzo V, Linari A,
Vigna E, Ladanyi M, Tuschl T and Ponzetto C: The muscle-specific
microRNA miR-206 blocks human rhabdomyosarcoma growth in
xenotransplanted mice by promoting myogenic differentiation. J Clin
Invest. 119:2366–2378. 2009.PubMed/NCBI
|
|
16
|
Hidaka H, Seki N, Yoshino H, Yamasaki T,
Yamada Y, Nohata N, Fuse M, Nakagawa M and Enokida H: Tumor
suppressive microRNA-1285 regulates novel molecular targets:
Aberrant expression and functional significance in renal cell
carcinoma. Oncotarget. 3:44–57. 2012.PubMed/NCBI
|
|
17
|
Chen X, Yan Q, Li S, Zhou L, Yang H, Yang
Y, Liu X and Wan X: Expression of the tumor suppressor miR-206 is
associated with cellular proliferative inhibition and impairs
invasion in ERα-positive endometrioid adenocarcinoma. Cancer Lett.
314:41–53. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vickers MM, Bar J, Gorn-Hondermann I,
Yarom N, Daneshmand M, Hanson JE, Addison CL, Asmis TR, Jonker DJ,
Maroun J, et al: Stage-dependent differential expression of
microRNAs in colorectal cancer: Potential role as markers of
metastatic disease. Clin Exp Metastasis. 29:123–132. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang L, Liu X, Jin H, Guo X, Xia L, Chen
Z, Bai M, Liu J, Shang X, Wu K, et al: miR-206 inhibits gastric
cancer proliferation in part by repressing cyclinD2. Cancer Lett.
332:94–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang X, Ling C, Bai Y and Zhao J:
MicroRNA-206 is associated with invasion and metastasis of lung
cancer. Anat Rec (Hoboken). 294:88–92. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Georgantas RW III, Streicher K, Luo X,
Greenlees L, Zhu W, Liu Z, Brohawn P, Morehouse C, Higgs BW,
Richman L, et al: MicroRNA-206 induces G1 arrest in melanoma by
inhibition of CDK4 and Cyclin D. Pigment Cell Melanoma Res.
27:275–286. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu J, Yang T, Li X, Yang Q, Liu R, Huang
J, Li Y, Yang C and Jiang Y: Alteration of serum miR-206 and
miR-133b is associated with lung carcinogenesis induced by
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Toxicol Appl
Pharmacol. 267:238–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou JY, Chen X, Zhao J, Bao Z, Chen X,
Zhang P, Liu ZF and Zhou JY: MicroRNA-34a overcomes HGF-mediated
gefitinib resistance in EGFR mutant lung cancer cells partly by
targeting MET. Cancer Lett. 351:265–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yan D, Dong Xda E, Chen X, Wang L, Lu C,
Wang J, Qu J and Tu L: MicroRNA-1/206 targets c-Met and inhibits
rhabdomyosarcoma development. J Biol Chem. 284:29596–29604. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Skead G and Govender D: Gene of the month:
MET. J Clin Pathol. 68:405–409. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakamura Y, Niki T, Goto A, Morikawa T,
Miyazawa K, Nakajima J and Fukayama M: c-Met activation in lung
adenocarcinoma tissues: An immunohistochemical analysis. Cancer
Sci. 98:1006–1013. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma PC, Jagadeeswaran R, Jagadeesh S,
Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K,
Lader A, et al: Functional expression and mutations of c-Met and
its therapeutic inhibition with SU11274 and small interfering RNA
in non-small cell lung cancer. Cancer Res. 65:1479–1488. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ichimura E, Maeshima A, Nakajima T and
Nakamura T: Expression of c-met/HGF receptor in human non-small
cell lung carcinomas in vitro and in vivo and its prognostic
significance. Jpn J Cancer Res. 87:1063–1069. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zillhardt M, Christensen JG and Lengyel E:
An orally available small-molecule inhibitor of c-Met, PF-2341066,
reduces tumor burden and metastasis in a preclinical model of
ovarian cancer metastasis. Neoplasia. 12:1–10. 2010. View Article : Google Scholar : PubMed/NCBI
|
